SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-066494
Filing Date
2023-08-14
Accepted
2023-08-14 08:12:33
Documents
39
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0623_rasnatherap.htm   iXBRL 10-Q 343500
2 CERTIFICATION f10q0623ex31-1_rasnatherap.htm EX-31.1 9716
3 CERTIFICATION f10q0623ex32-1_rasnatherap.htm EX-32.1 3387
  Complete submission text file 0001213900-23-066494.txt   2054132

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rasp-20230630.xsd EX-101.SCH 26394
5 XBRL CALCULATION FILE rasp-20230630_cal.xml EX-101.CAL 19974
6 XBRL DEFINITION FILE rasp-20230630_def.xml EX-101.DEF 100180
7 XBRL LABEL FILE rasp-20230630_lab.xml EX-101.LAB 226885
8 XBRL PRESENTATION FILE rasp-20230630_pre.xml EX-101.PRE 108311
33 EXTRACTED XBRL INSTANCE DOCUMENT f10q0623_rasnatherap_htm.xml XML 143858
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 231166449
SIC: 2834 Pharmaceutical Preparations